Gerald Artman is a seasoned pharmaceutical leader with a proven track record of advancing small molecule therapies from pre-IND through commercial launch. With extensive experience at both large pharmaceutical organizations (Novartis, Celgene/Bristol Myers Squibb, GSK) and innovative biotechs (Bellus Health, Reata Pharmaceuticals, Sionna Therapeutics), Jerry has served as a cross-functional CMC subject matter expert, designing patentable, scalable, and cost-effective manufacturing processes across all clinical phases.

At Reata Pharmaceuticals, Gerald led CMC strategy as the primary R&D, manufacturing, and authoring SME, culminating in the submission of two NDAs—including the successful approval of Skyclarys™ (omaveloxolone), the first and only FDA-approved treatment for Friedreich’s ataxia (2023, Reata/Biogen). He also played a pivotal role in the $2 billion acquisition of Bellus Health by GSK, recognized as a key CMC contributor during due diligence for the Phase 3 asset camlipixant.

Gerald excels in global CDMO leadership, overseeing operations across Asia, Europe, and North America while navigating time zones, cultural dynamics, and regulatory shifts—including the BioSecure Act and evolving U.S. tariff policies. He has built a robust, geographically diverse network of trusted manufacturing partners to ensure supply chain resilience for APIs, key materials, and drug products.

Driven by a passion to deliver life-changing therapies to patients in need, Gerald combines scientific rigor, operational discipline, and strategic foresight to accelerate development and secure long-term success.